Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact on the intestinal microbiota during antibiotic treatment
2016-003704-31Phase 2Completed
- Sponsor
- Uppsala University
- Start
- Jan 2017
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of ciprofloxacin, pivmecillinam and ceftibuten in bacterial disease (3 arms), sponsored by Uppsala University. Primary endpoints: Intestinal microbiota diversity and composition, Prevalence of multidrug-resistant Gram-negative bacteria and 1 more. Started Jan 2017; status: completed.
02
Drugs
ciprofloxacinpivmecillinamceftibuten
03
Conditions
bacterial disease
Beyond the preview
Go deeper on 2016-003704-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003704-31.